Status:
COMPLETED
A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis
Lead Sponsor:
UCB Biopharma SRL
Conditions:
Psoriatic Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a study to assess the long-term safety and tolerability of bimekizumab in subjects with psoriatic arthritis
Eligibility Criteria
Inclusion
- In the opinion of the Investigator, the subject is expected to benefit from participation in an Open Label Extension (OLE) study
- Subject completed PA0008 without meeting any withdrawal criteria
- Female subjects must be postmenopausal, permanently sterilized or, if of childbearing potential, must be willing to use a highly effective method of contraception
- Male subjects with a partner of childbearing potential must be willing to use a condom when sexually active
Exclusion
- Female subjects who plan to become pregnant during the study or within 20 weeks following the last dose of IMP. Male subjects who are planning a partner pregnancy during the study or within 20 weeks following the last dose
- Subjects with any current sign or symptom that may indicate a medically significant active infection (except for the common cold) or has had an infection requiring systemic antibiotics within 2 weeks of study entry
- Subjects who meet any withdrawal criteria in PA0008. For any subject with an ongoing Serious Adverse Event, or a history of serious infections (including hospitalizations) in the lead-in study, the Medical Monitor must be consulted prior to the subject's entry into PA0009
Key Trial Info
Start Date :
November 22 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 29 2020
Estimated Enrollment :
184 Patients enrolled
Trial Details
Trial ID
NCT03347110
Start Date
November 22 2017
End Date
October 29 2020
Last Update
December 1 2023
Active Locations (37)
Enter a location and click search to find clinical trials sorted by distance.
1
Pa0009 025
Lexington, Kentucky, United States, 40504
2
Pa0009 003
Hagerstown, Maryland, United States, 21502
3
Pa0009 011
Lansing, Michigan, United States, 48910
4
Pa0009 028
Rochester, New York, United States, 14642